business, pharma

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

Pfizer says it won’t continue its pursuit to purchase AstraZeneca—at least for now.

How to successfully surmount the challenges women face in becoming biotech industry leaders

The surprising results when drug development and altruism collide